Podcasts about AAV

The guys wrap up their 2025/26 season preview as we jump into the Metro Division.First we start with some of the biggest headlines from around the league including Sidney Crosby, Quinn Hughes and the Vancouver Canucks and a Jack Eichel extension in Vegas.Then we move to the Kirill Kaprizov contract rumours. It was reported that he turned down 8 years at a $16 million AAV. Is there truth to this rumor and is it a term or a dollar issue?We then jump into our preview of the Metro Division starting at the bottom with the Philadelphia Flyers and working our way up to the Washington Capitals.Some major news within the division includes the Dan Vladar trade to Philadelphia, the Crosby trade rumors, Matthew Schaefer joining the New York Islanders, the Luke Hughes contract, potential landing spots for Carter Hart and more!Producer, Patrick Puff, then joins for a quick rendition of ‘Fill in the Blank' to discuss which teams will be the most improved this season, who else would have been a great captain for the New York Rangers and where Sidney Crosby could land if he were to move. This also sparked a brief conversation about Connor McDavid's next contract.Which teams will be the most improved and which teams will be headed for the Gavin McKenna sweepstakes next summer?2:00 - Around the League - ( Eichel/Kempe/Hughes)5:00 - Kirill Kaprizov Contract 11:20 - Philadelphia Flyers15:40 - Pittsburgh Penguins19:45 - Sidney Crosby Rumours (Montreal)20:30 - New York Islanders24:45 - New York Rangers28:00 - Fill in the Blank34:00 - Connor McDavid Contract Talk35:45 - Columbus Blue Jackets39:45 - New Jersey Devils43:45 - Carolina Hurricanes ( Kaprizov Landing Spot? )49:00 - Washington CapitalsWant to hear more from Jason and the entire DFO team? Subscribe to our YouTubeYou can get involved with all the NHL futures action over on bet365 by using the promo code NATION at bet365.comConnect with us on ⬇️TwitterInstagramWebsiteDaily Faceoff Merch Hosted on Acast. See acast.com/privacy for more information.

Hour 1 of the Big Show with George Rusic & Matt Rose is on demand! To kick off show the guys react to a piece of news out of Minnesota. Kirill Kaprizov reportedly rejected a 16 million dollar AAV contract to extend with the Wild. The guys then discuss what the potential UFA class could look like in 2026 if McDavid Kaprizov and more premiere players hit the open market.(28:08) Later on, Matty Rose gets you all caught up on the world of sports in the Rose Report!  The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.    

Thursday afternoon means a fresh episode of Real Life was recorded, edited, and is ready to help you kick off your workweek. On today's podcast, the guys discussed the start of the NFL season, jersey purchases, Pink Pony Club origin, and delved into any other topics that arose.The guys kicked off the Thursday episode of Real Life by discussing the best time of the year for sports, now that the NHL is underway, the Jays are chasing a division win, and the NFL season has begun. There are so many sports stories to be excited about, and the guys kicked off the podcast with a conversation about Shadeur Sanders' jersey being a top seller despite not even being the starting QB in Cleveland. Talking about jerseys led the boys to talk about which unis they would buy if they were in the market for a new one. Changing gears, the guys looked at the Connor McDavid contract situation and wondered whether or not these delays are tied to Kirill Kaprisov's stalemate in Minnesota. Yesterday, it was reported that the Wild star turned down a $16 million AAV over eight years, which led to a conversation about whether these two contracts are linked. If Kaprisov is turning down that much smoke, does that mean that Connor McDavid is waiting to see where he lands before signing his own extension?Finally, the guys wrapped up the Thursday episode of Real Life with a random collection of topics, including Coldplay being set to pass Taylor Swift's tour gross earnings, Connor Brown spilling the Pink Pony Club details, the Real Life Fantasy Football League, and the new Charlie Sheen documentary that just got loaded to Netflix. The squad may have been shorthanded this week, but that didn't stop them from yammering on about anything and everything for an hour. Hosted on Acast. See acast.com/privacy for more information.

This week on 2 Guys & A Goalie, the crew dives into the wild rumour that Kirill Kaprizov apparently turned down a $16-million AAV deal. What does it say about his value, and could we ever see an NHL player push for that kind of money?   Plus, with rookie camps underway across the NHL, we swap some of the best stories from past rookie camps — from standout performances to unforgettable moments that gave fans a first look at future stars.   2 Guys & a Goalie is presented by GS Construction!

Thursday afternoon means a fresh episode of Real Life was recorded, edited, and is ready to help you kick off your workweek. On today's podcast, the guys discussed the start of the NFL season, jersey purchases, Pink Pony Club origin, and delved into any other topics that arose.The guys kicked off the Thursday episode of Real Life by discussing the best time of the year for sports, now that the NHL is underway, the Jays are chasing a division win, and the NFL season has begun. There are so many sports stories to be excited about, and the guys kicked off the podcast with a conversation about Shadeur Sanders' jersey being a top seller despite not even being the starting QB in Cleveland. Talking about jerseys led the boys to talk about which unis they would buy if they were in the market for a new one. Changing gears, the guys looked at the Connor McDavid contract situation and wondered whether or not these delays are tied to Kirill Kaprisov's stalemate in Minnesota. Yesterday, it was reported that the Wild star turned down a $16 million AAV over eight years, which led to a conversation about whether these two contracts are linked. If Kaprisov is turning down that much smoke, does that mean that Connor McDavid is waiting to see where he lands before signing his own extension?Finally, the guys wrapped up the Thursday episode of Real Life with a random collection of topics, including Coldplay being set to pass Taylor Swift's tour gross earnings, Connor Brown spilling the Pink Pony Club details, the Real Life Fantasy Football League, and the new Charlie Sheen documentary that just got loaded to Netflix. The squad may have been shorthanded this week, but that didn't stop them from yammering on about anything and everything for an hour. Hosted on Acast. See acast.com/privacy for more information.

Ataxia is a neurologic symptom that refers to incoordination of voluntary movement, typically causing gait dysfunction and imbalance. Genetic testing and counseling can be used to identify the type of ataxia and to assess the risk for unaffected family members. In this episode, Katie Grouse, MD, FAAN, speaks with Theresa A. Zesiewicz, MD, FAAN, author of the article “Ataxia” in the Continuum® August 2025 Movement Disorders issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Zesiewicz is a professor of neurology and director at the University of South Florida Ataxia Research Center, and the medical director at the University of South Florida Movement Disorders Neuromodulation Center at the University of South Florida and at the James A. Haley Veteran's Hospital in Tampa, Florida. Additional Resources Read the article: Ataxia Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Theresa Zesiewicz about her article on ataxia, which appears in the August 2025 Continuum issue on movement disorders. Welcome to the podcast, and please introduce yourself to our audience.  Dr Zesiewicz: Well, thank you, Dr Grouse. I'm Dr Theresa Zesiewicz, otherwise known as Dr Z, and I'm happy to be here. Dr Grouse: I have to say, I really enjoyed reading your article. It was a really great refresher for myself as a general neurologist on the topic of ataxia and a really great reminder on a great framework to approach diagnosis and management. But I wanted to start off by asking what you feel is the key message that you hope our listeners will take away from reading your article. Dr Zesiewicz: Yes, so, thanks. I think one of the key messages is that there has been an explosion and renaissance of genetic testing in the past 10 years that has really revolutionized the field of ataxia and has made diagnosis easier for us, more manageable, and hopefully will lead to treatments in the future. So, I think that's a major step forward for our field in terms of genetic techniques over the last 10 years, and even over the last 30 years. There's just been so many diseases that have been identified genetically. So, I think that's a really important take-home message. The other take-home message is that the first drug to treat Friedreich's ataxia, called omaveloxolone, came about about two years ago. This was also a really landmark discovery. As you know, a lot of these ataxias are very difficult to treat. Dr Grouse: Now pivoting back to thinking about the approach to diagnosis of ataxia, how does the timeline of the onset of ataxia symptoms inform your approach? Dr Zesiewicz: The timeline is important because ataxia can be acute, subacute or chronic in nature. And the timeline is important because, if it's acute, it may mean that the ataxia took place over seconds to hours. This may mean a toxic problem or a hypoxic problem. Whereas a chronic ataxia can occur over many years, and that can inform more of a neurodegenerative or more of a genetic etiology. So, taking a very detailed history on the patient is very important. Sometimes I ask them, what is the last time you remember that you walked normal? And that can be a wedding, that can be a graduation. Just some timeline, some point, that the patient actually walked correctly before they remember having to hold onto a railing or taking extra steps to make sure that they didn't fall down, that they didn't have imbalance. That sometimes that's a good way to ask the patient when is the last time they had a problem. And they can help you to try to figure out how long these symptoms have been going on. Dr Grouse: I really appreciate that advice. I will say that I agree, it can sometimes be really hard to get patients to really think back to when they really started to notice something was different. So, I like the idea of referencing back to a big event that may be more memorable to them. Now, given that framework of, you know, thinking through the timeline, could you walk us through your approach to the evaluation of a patient who presents to your clinic with that balance difficulties once you've established that? Dr Zesiewicz: Sure. So, the first thing is to determine whether the patient truly has ataxia. So, do they have imbalance? Do they have a wide base gait? That's very important because patients come in frequently to your clinic and they'll have balance problems, but they can have knee issues or hip issues, neuropathy, something like that. And sometimes what we say to the residents and the students is, usually ataxia or cerebellar symptoms go together with other problems, like ocular problems are really common in cerebellar syndromes. Or dysmetria, pass pointing, speech disorder like dysarthria. So, not only do you need to look at the gait, but you should look at the other symptoms surrounding the gait to see if you think that the patient actually has a cerebellar syndrome. Or do they have something like a vestibular ataxia which would have more vertigo? Or do they have a sensory ataxia, which would occur if a person closes his eyes or has more ataxia when he or she is in the dark? So, you have to think about what you're looking at is the cerebellar syndrome. And then once we look to see if the patient truly has a cerebellar syndrome, then we look at the age, we look at---as you said before, the timeline. Is this acute, subacute, or chronic? And usually I think of ataxia as falling into three categories. It's either acquired, it's either hereditary, or it's neurodegenerative. It can be hereditary. And if it's not hereditary, is it acquired, or is it something like a multiple system atrophy or a parkinsonism or something like that? So, we try to put that together and start to narrow down on the diagnosis, thinking about those parameters. Dr Grouse: That's really a helpful way to think through it. And it is true, it can get very complex when patients come in with balance difficulties. There's so many things you need to think about, but that is a great way to think about it. Of course, we know that most people who come in to the Movements Disorders clinic are getting MRI scans of their brains. But I'm curious, in which cases of patients with cerebellar ataxia do you find the MRI to be particularly helpful in the diagnosis? Dr Zesiewicz: So, an MRI can be very important. Not always, but- so, something like multiple system atrophy type C where you may see a hot cross bun sign or a pontine hyperintensity on the T2-weighted image, that would be helpful. But of course, that doesn't make the diagnosis. It's something that may help you with the diagnosis. In FXTAS, which is fragile X tremor/ataxia syndrome, the patient may have the middle cerebellar peduncle sign or the symmetric hyperintensity in the middle cerebellar peduncles, which is often visible but not always. Something like Wernicke's, where you see an abnormality of the mammillary bodies. Wilson's disease, which is quite rare, T2-weighted image may show hyperintensities in the putamen in something like Wilson's disease. Those are the main MRI abnormalities, I think, with ataxia. And then we look at the cerebellum itself. I mean, that seems self-evident, but if you look at a sagittal section of the MRI and you see just a really significant atrophy of the cerebellum, that's going to help you determine whether you really have a cerebellar syndrome. Dr Grouse: That's really encouraging to hear a good message for all of us who sometimes feel like maybe we're missing something. It's good to know that information can always come up down the line to make things more clear. Your article does a great review of spinal cerebellar ataxia, but I found it interesting learning about the more recently described syndrome of SCA 27B. Would you mind telling us more about that and other really common forms of SCA that's good to keep in mind? Dr Zesiewicz: Sure. So, there are now 49 types of spinal cerebellar ataxia that have been identified. The most common are the polyglutamine repeat diseases: so, spinocerebellar ataxia type 3 or type 2, type 6, are probably the most common. One of the most recent spinocerebellar ataxias to be genetically identified and clinically identified is spinocerebellar ataxia 27B. This is caused by a GAA expansion repeat in the first intron of the fibroblast growth factor on chromosome 13. And the symptoms do include ataxia, eye problems, downbeat nystagmus, other nystagmus, vertical, and diplopia. It appears to be a more common form of adult-onset ataxia, and probably more common than was originally thought. It may account for a substantial number of ataxias, like, a substantial percentage of ataxias that we didn't know about. So, this was really a amazing discovery on SCA 27B. Dr Grouse: Now a lot of us I think feel a little anxious when we think about genetic testing for ataxia simply because there's so many forms, things are changing quickly. Do you have a rule of thumb or a kind of a framework that we can think of as we approach how we should be thinking about getting genetic testing for the subset of patients? Dr Zesiewicz: Sure. And I think that this is where age comes into play a lot. So, if you have a child who's 10, 11, or 12 who's having balance problems in the schoolyard, does not have a history of ataxia in the family, the teachers are telling you that the child is not running correctly, they're having problems with physical education, that is someone who you would think about testing for Friedreich's ataxia. A preteen or a child, that would be one thing that would be important to test. When you talk to your patient, it's important to really take a detailed family history. Not just mom or dad, but ethnicity, grandparents, etc. And sometimes, once in a while, you come up with a known spinal cerebellar ataxia. Then you can just test for that. So, if a person is from Portugal or has Portugal background and they have ataxia and the parents had ataxia, you would think of spinal cerebellar ataxia type 3. Or if they're Brazilian, or if the person is from a certain area of Cuba and mom and dad had ataxia and that person has ataxia, you would think of spinal cerebellar ataxia type 2. Or if a person has ataxia and their parent had blindness or visual problems, you may be more likely to think of spinal cerebellar ataxia type 7, for example. If they have that---either they have a known genetic cause in in the family, first degree family, or they come from an area of the world in which we can pinpoint what type we think it is---you can go ahead and get those tests. If not, you can take an ataxia comprehensive panel. Many times now, if you take the panel and the panel is negative, it will reflex to the whole exome gene sequencing, where we're finding really unusual and more rare types of ataxia, which are very interesting. Spinal cerebellar ataxia type 32, spinal cerebellar ataxia type 36, I had a spinal cerebellar ataxia type 15. So, I think you should start with the age, then the family history, then where the person is from. And then, if none of those work out, you can get a comprehensive panel, and then go on to whole exome gene sequencing. Dr Grouse: That's really, really useful. Thank you so much for breaking that down in a really simple way that a lot of us can take with us. Pivoting a little bit now back towards different types of acquired ataxias, what are some typical lab tests that you recommend for that type of workup? Dr Zesiewicz: Again, if there's no genetic history and the person does not appear to have a neurodegenerative disease, we do test for acquired ataxias. Acquired ataxias can be complex. Many times, they are in the autoimmune family. So, what we start with are just basic labs like a CBC or a CMP, but then we tried to look at some of the other abnormalities that could cause ataxia. So, celiac disease, stiff person syndrome. So, you would look at anti-glutamic acid decarboxylase antibodies, Hashimoto's---so, antithyroglobulin antibodies or antithyroperoxidase antibodies would be helpful. You know, in a case of where the patients may have an underlying neoplasm, maybe even a paraneoplastic workup, such as an anti-Hu, anti-Yo, anti-Ri. A person has breast cancer, for example, you may want to take a paraneoplastic panel. I've been getting more of the anti-autoimmune encephalitis panels in some cases, that were- that are very interesting. And then, you know, things that sometimes we forget now like the syphilis test, thyroid-stimulating test, take a B12 and folate, for example. That would be important. Those are some of the labs. We just have on our electronic chart a group of acquired labs for ataxia. If we can't find any other reason, we just go ahead and try to get those. Dr Grouse: Now, I'm curious what you think is the most challenging aspect of diagnosing a patient with cerebellar ataxia? Dr Zesiewicz: So, for those of us who see many of these patients a day, some of the hardest patients are the ones that---regardless of the workup that we do, we've narrowed it down, it's not hereditary. You know, they've been through the whole exome gene sequencing and we've done the acquired ataxia workup. It doesn't appear to be that. And then we've looked for parkinsonism and neurodegenerative diseases, and it doesn't appear to be that either; like, the alpha-synuclein will be negative. Those are the toughest patients, where we think we've done everything and we still don't have the answer. So, I've had patients in whom I've taken care of family members years and years ago, they had a presumed diagnosis, and later on I've seen their children or other family members. And with the advent of the genetic tests that we have, like whole exome gene sequencing, we have now been able to give the patient and the family a definitive diagnosis that they didn't have 25 years ago. So, I would say don't give up hope. Retesting is important, and as science continues and we get more information and we make more landmark discoveries in genetics, you may be better able to diagnose the patient. Dr Grouse: I was wondering if you had any recommendations regarding either some tips and tricks, some pearls of wisdom you can impart to us regarding the work of ataxia, or conversely, any big pitfalls that you can help us avoid? I would love to hear about it. Dr Zesiewicz: Yeah, there's no easy way to treat or diagnose ataxia patients. I've always felt that the more patients you see- and sounds easy, but the more patients you see, the better you're going to become at it, and eventually things are going to fall into place. You'll begin to see similarities in patients, etc. I think it's important not only to make sure that a person has ataxia, but again, look at the other signs and symptoms that may point to ataxia that you'll see in a cerebellar syndrome. I think it's important to do a full neuroexam. If a person has spasticity, that may point you more towards a certain type of ataxia than if a person has no reflexes, for example, that we see in Friedreich's ataxia. Some of the ocular findings are very interesting as well. It's important to know if a person has a tremor. I've seen several Wilson's disease cases in my life with ataxia. They're very important. I think a full neuroexam and also a very detailed history would be very helpful. Dr Grouse: Tell us about some promising developments in the diagnosis and management of ataxia that we should be on the lookout for. Dr Zesiewicz: The first drug for Friedreich's ataxia was FDA-approved two years ago, which was an NRF2 activator, which was extremely exciting and promising. There are also several medications that are now in front of the FDA that may also be very promising and have gone through long clinical trials. There's a medication that's related to riluzole, which is a medication used for amyotrophic lateral sclerosis, that has been through about seven years of testing. That is before the FDA as well for spinal cerebellar ataxia. Friedreich's ataxia has now completed the first cardiac gene therapy program with AAV vectors, which- we're waiting for full results, but that's a cardiac test. But I would assume that in the future, neurological gene therapy is not far behind if we've already done cardiac gene therapy and Friedreich's ataxia. So, you know, some of these AAV vector-based genetic therapies may be very helpful, as well as ASO, antisense oligonucleotides, for example. And I think in the future, other things to think about are the CRISPR/Cas9 technology for potential treatment of ataxia. It is a very exciting time, and some major promising therapies have been realized in the past 2 to 3 years. Dr Grouse: Well, that's really exciting, and we'll all look forward to seeing these becoming more clinically applicable in the future. So, thank you so much for coming to talk with us today. Dr Zesiewicz: Thank you. Dr Grouse: Again, today I've been interviewing Dr Theresa Zesiewicz about her article on ataxia, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Kerbs joins the show to discuss the report that Kirill Kaprizov turned down 8x16 with the Wild. What does this mean for the Wild? Plus, do we see more players start taking short term deals with high AAV like we have seen in the NBA?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On hour two of Sportsnet Today, Logan Gordon is joined by our very own Pat Steinberg to continue to dive into Dustin Wolf's new extension! Pat brings the latest on how the deal came together, his impressions of the term and the AAV, and if Wolf has solidified himself as Calgary's franchise goaltender.(25:39) Logan and Shan get you caught up on all the latest news around the Toronto Blue Jays ahead of their series against the Houston Astros! The guys bring an update on Bo Bichette's injury status, lineup changes, and more! Plus, their reactions to the drama on MNF as the Vikings take down the Bears!The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate. Catch every episode of Sportsnet Today live on Sportsnet 960 from 1-3pm MST! Hour 1 Music: Island Life - Atomic Drum AssemblyHour 2 Music: Egozi - Jell O Logan: @Fan960Logan on X Produced by Cameron Hughes and Shan Virjee.

In this Summer Coolers edition of NHL Wraparound, hosts Neil Smith and Vic Morren review the offseason, roster structure, and playoff hopes of the Columbus Blue Jackets—a team that came painfully close to breaking their five-year postseason drought in 2024–25.The Blue Jackets finished with 89 points, just two shy of the final wild card spot, and were eliminated by a regulation win tiebreaker after going winless against the St. Louis Blues in the season series. Despite the heartbreak, the Jackets were one of the NHL's surprise teams, boasting an offense that tied for 7th in the league (3.26 GPG) and scoring six or more goals in 16 games.This episode examines Columbus's offseason decisions, including the high-profile Charlie Coyle–Miles Wood trade with Colorado, the questionable seven-year, $8.5M deal for Ivan Provorov, and the tragic loss of Johnny Gaudreau, which emotionally galvanized the team early in the season.Can this team stay healthy and consistent for all 82 games? And does head coach Ken Evison have another motivational gear without the emotional backdrop of last year?IN THIS EPISODE:[00:00] Columbus recap: Falling short of the wild card[00:38] Offensive strides and surprising firepower[01:00] Coyle & Wood in, Brindley & picks out in trade with Colorado[01:45] Reviewing free agent signings: Hudson Fasching and re-signings[02:30] The shock of the Provorov deal: 7 years, $8.5M AAV[03:30] Tragic loss of Johnny Gaudreau and impact on locker room[04:00] Goalie update: Jet Greaves promoted behind Elvis Merzlikins[05:00] Deadline departures: Tarasov, Kuraly, JVR, Danforth, Harris[06:00] What might have been: injuries to Monahan and Jenner[06:30] Playoff odds: Can they push over the line this time?[07:00] Shoutout: Matthew Olivier's breakout year and fan favorite statusKEY TAKEAWAYS:Columbus made strides offensively last season but lacked late-season consistency, finishing the final stretch 4–11–1 before winning six straight.The Provorov contract surprised many: a long-term, high-AAV commitment for a player with declining impact.Injuries to Boone Jenner and Sean Monahan derailed what was shaping up to be a playoff-bound season.Players like Kent Johnson, Marchenko, Fantilli, and Sillinger will need to continue developing for the team to reach the next level.Matthew Olivier and Miles Wood are expected to form one of the toughest fourth lines in the NHL, offering a physical edge.In a crowded Metro Division, the Blue Jackets' playoff hopes are real—but so are the risks of another near miss.RESOURCE LINKS:YouTube: https://www.youtube.com/channel/UCgBj1LV0-DMfBhcRPSJZLjAX (Twitter): https://twitter.com/NHLWraparoundNeil Smith: https://twitter.com/NYCNeilVic Morren: https://www.linkedin.com/in/vic-morren-7038737/Instagram: https://www.instagram.com/nhlwraparound/TikTok: https://www.tiktok.com/@nhlwraparoundFacebook: https://www.facebook.com/profile.php?id=61555451139787#NHL #Hockey #Podcast #ColumbusBlueJackets #CharlieCoyle #MilesWood #GavinBrindley #HudsonFasching #IvanProvorov #DanteFabbro #OwenSillinger #DmitriVoronkov #DaemonHunt #JohnnyGaudreau #MatthewGaudreau #DeanEvason #SeanMonahan #KirillMarchenko #YegorChinakov #AdamFantilli #KentJohnson #BooneJenner #ZachWerenski #DaniilTarasov #ElvisMerzlikins #JetGreaves #SeanKuraly #JordanHarris #PatrikLaine #JustinDanforth #JamesvanRiemsdyk #MathieuOlivier

On hour one of Flames Talk, Pat Steinberg and Aaron Vickers kick off the hour reacting to Connor Zary's new three-year deal worth $3.775 million AAV. The guys dive into why it's a win for both the player and the team, what it means for Zary's role this season, and debate if he'll see more time as a winger or a centre!(27:42) Plus, the guys dive into some leftover texts from Thursday's Mailbag; Rasmus Andersson's contract and potential destinations, new assistant coach Dave Lowry, and more!The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate. https://www.sportsnet.ca/960/flames-talk/

In this episode of Starcastic Remarks, Ryan and Chris tackle the two biggest contract questions facing the Dallas Stars: Jason Robertson and Thomas Harley. Will Robertson push into $11–12 million territory, and is Harley's breakout season enough to lock him in long-term at a higher AAV than Miro Heiskanen? The conversation also explores Jamie Benn's future as captain, his shift toward a bottom-six role, and whether his leadership still makes him indispensable to the team. Along the way, the guys react to Joe Pavelski's Hall of Fame nod, Switzerland's puzzling ban on Lian Bichsel, and the NHL's new playoff salary cap rules. As September begins and hockey draws closer, the focus sharpens on what extensions, roster moves, and leadership decisions will define the Stars' 2025–26 campaign. We're Looking for sponsors! If you or your business want to partner with a passionate, growing hockey podcast with a loyal Dallas Stars fanbase, we'd love to connect. Check out our media kit by clicking here to learn how you can support Starcastic Remarks and reach a dedicated NHL audience. JOIN THE Who CARES Club! Love Starcastic Remarks? Join our membership club, The Who Cares Club! For $5/month, you get some exclusive perks and help the most sarcastic Stars podcast continue to grow and continue on! Click here to join! Support Starcastic Remarks! Help us grow by leaving a 5-star review wherever you listen to podcasts—it makes a huge difference! Watch us on YouTube and click like & subscribe and hit that notification bell! Follow us across social media for updates, highlights, and behind-the-scenes content: YouTube: @StarcasticR Twitter (X): @StarcasticR Discord: Join Here TikTok: @StarcasticR Instagram: @StarcasticR Facebook: @StarcasticR Visit our website here for more content!

Send us a textIt actually happened! Steven & Derek discuss the Cowboys trading Micah Parsons to the Packers for 2 1st round picks & Kenny Clark. Parsons receives a 4 year-$188 million dollar deal, 136 million guaranteed with an AAV of 47 million. How did it get to this? Does it remind us of the Khalil Mack trade? Is it the NFL equivalent of the Luka Doncic trade?  Support the show

Steve and Joe go through our TOP 5 players we are TERRIFIED to draft in auction drafts based on average auction value (AAV) for the 2025 Fantasy Football season!Subscribe to our YouTube page to catch all of the latest Front Office Pros videos, including future livestreams: https://www.youtube.com/@frontofficeprosWatch here on YouTube -> https://youtu.be/X_l95E-bxu0FOLLOW US ON SOCIAL MEDIA:- X: https://x.com/FrontOfficePros- Instagram: https://www.instagram.com/frontofficepros/- TikTok: https://www.tiktok.com/@frontofficeprosMUSIC PROVIDED BY:https://www.beatstars.com/dinerbeats

It's another Wednesday in the middle of the NHL dead zone, which means a fresh episode of Better Lait Than Never is ready to recap what was another non-event news week in Edmonton. On today's podcast, I discussed Tyler's Ace Race, patiently waiting for Oilers news, extension rumours, and whatever else has happened over the last seven days.There isn't much happening in Edmonton Oilers land these days, which meant a very quick recap of the news and stories that happened over the last two weeks. While we still wait for Connor McDavid's contract extension, more insiders are starting to chime in with what they think this new deal is going to look like, including John Shannon's speculation that the AAV will be lower than many expect. I also touched on a recent interview Stuart Skinner gave at NHL.com, where the Oilers' goalie spoke about being confident that the group will be able to respond after a second consecutive Stanley Cup Final loss.Finally, I wrapped up this week's episode of BLTN with a guest Righteous Sack Beating before wrapping up the podcast with another round of voicemails. The voicemail was alive with nonsense this week, and as always, the messages were as fun as ever. The voicemails are a fun way to wrap up the show and give everyone a chance to share their thoughts. Another hearty thank you to everyone who contributed to this week's episode, because having all of you in the mix makes the show so much better.

"My friends are toys. I make them. It's a hobby. I'm a genetic designer." This is a two part podcast covering the important factors is successful gene therapy and introduces the knowledge gained from other neuromuscular diseases and how it can be used to positively impact gene therapy in FSHD. In part 1, we focus on AAV serotypes, transgene constructs, immune responses, and delivery. We look into DMD gene therapy and how that can impact the current FSHD gene therapy programs. Check us out on the MyFSHD Youtube channel as well.

Vinay Prasad is back at the FDA as chief of the FDA's Center for Biologics Evaluation and Research. Prasad's return—which hit the news wires Saturday morning—came just 10 days after his unexpected exit on July 29, following blowback over the saga involving Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy Elevidys, and a campaign by conversative personalities to oust the outspoken physician.Elsewhere in the government, Gray Delany, former head of HHS' and President Donald Trump's Make America Healthy Again agenda, has been fired—days after Health and Human Services Secretary Robert F. Kennedy Jr. axed 22 mRNA vaccine contracts under the Biomedical Advanced Research and Development Authority. Delany's ouster came after he allegedly butted heads with other agency officials over how announcements were made, according to reporting from Endpoints News. The mRNA contract cuts, meanwhile, have sparked criticism from the scientific community and concern that the growing anti-mRNA sentiment could also have a negative effect on research for cancer therapeutics.In somewhat related news, the Annals of Internal Medicine is refusing to retract a large-scale study it ran in July that pointed to the lack of an association between childhood aluminum exposure through vaccination and chronic conditions, despite Kennedy's criticism. In an op-ed published earlier this month, the Health Secretary took issue with the study's design.In obesity news, biopharma darling Eli Lilly suffered a rare chink in its normally impenetrable GLP-1 armor. The first Phase III trial for oral weight loss therapy orforglipron read out last week, and the results were underwhelming, at least to Wall Street. Truist Securities wrote that the data support approval but “leaves room for competition.” This is good news for a whole host of companies, including Roche, Viking, Terns and Rhythm Pharmaceuticals, who all have weight loss pills at various stages of development.And in gene therapy, the hits just keep coming. The FDA has limited the use of bluebird bio's gene therapy Skysona to patients with cerebral adrenoleukodystrophy for whom no other therapies or stem cell donors are available, due to a heightened risk of blood cancers. This follows safety issues in gene therapy trials experienced by Allogene, and, of course, Sarepta Therapeutics. This week in ClinicaSpace, Dan Samorodnitsky explored the future of AAV technology. And in BioPharm Executive, Annalee Armstrong sat down with Chris Anzalone, CEO of Arrowhead Pharmaceuticals—Sarepta's key strategic partner—to learn how his company has been weathering the storm.

Steve and Joe share 5 auction values that we are not paying according to ESPN's average auction value (AAV) for the 2025 Fantasy Football season!Subscribe to our YouTube page to catch all of the latest Front Office Pros videos, including future livestreams: https://www.youtube.com/@frontofficeprosWatch here on YouTube -> https://youtu.be/5G-jWjasCxUFOLLOW US ON SOCIAL MEDIA:- X: https://x.com/FrontOfficePros- Instagram: https://www.instagram.com/frontofficepros/- TikTok: https://www.tiktok.com/@frontofficeprosMUSIC PROVIDED BY:https://www.beatstars.com/dinerbeats

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vinay Prasad has returned to his position as director of the Center for Biologics Evaluation and Research at the FDA after a sudden exit less than two weeks ago. The FDA has restricted the patient pool for bluebird's Skysona gene therapy due to safety concerns, and Sarepta's AAV gene therapy platform has come under scrutiny following patient deaths from liver injuries. Genscript is celebrating a new era of innovation and trust.The text discusses the scrutiny faced by AAV gene therapy technology following patient deaths related to Sarepta Therapeutics' platform. There is a push for improvement in the technology, while some are looking to move on to other options. The article also highlights the importance of mRNA technology in cancer research and the need for continued investment in this area. Additionally, it mentions the FDA's decision on Biogen and Eisai's Alzheimer's drug, as well as five oral obesity drugs that could rival Lilly's Orforglipron. Other topics covered include cancer drug developments, gene therapy news, and upcoming industry events.Stay tuned for more updates on the latest news in the pharmaceutical and biotechnology industries.

Steve and Joe share 5 players bargain auction values that we are ALL IN on according to average auction value (AAV) from ESPN for the 2025 Fantasy Football season!Subscribe to our YouTube page to catch all of the latest Front Office Pros videos, including future livestreams: https://www.youtube.com/@frontofficeprosWatch here on YouTube -> https://youtu.be/VRZAaiiYZyAFOLLOW US ON SOCIAL MEDIA:- X: https://x.com/FrontOfficePros- Instagram: https://www.instagram.com/frontofficepros/- TikTok: https://www.tiktok.com/@frontofficeprosMUSIC PROVIDED BY:https://www.beatstars.com/dinerbeats

In today's over/under Casey Warner sets the lines on a WNBA trend, starts for Bucs Charlie Heck at LT, Benjamin Morrison's INT total, an updated Rays win-total, Micah Parsons new contract AAV and more!

Craig reacts to Diana Russini's latest reporting on the Terry McLaurin contract negotiations. Russini joined BMitch and Finlay and clarified that McLaurin is not asking for DK Metcalf-level AAV. Craig weighs in on her comments—especially her line about “who's got the stomach for it” in these talks. Plus, Craig and Anthony go back and forth on whether the Commanders can beat the Giants in Week 1 with—or without—Terry McLaurin.

Lucas Raymond has been recognized as one of the best contracts in the NHL, which begs the question: just how good is the Detroit Red Wings core's cap structure? Tune in as we discuss Steve Yzerman's position as he navigates a rising salary cap and what he has in Dylan Larkin, Lucas Raymond, and Moritz Seider long term, and how that affect his ability to attract future superstars or any free agent talent, extend Alex DeBrincat and Patrick Kane, sign Marco Kasper (Michigan goal-scorer), Nate Danielson, Axel Sandin Pellikka, and others after their ELCs, and more (4:05). Next, we go over Simon Edvinsson's next contract, when the best time for Steve Yzerman to sign him would be, what his AAV will look like next to Moritz Seider, how he fared with Albert Johansson, & more (33:35) before we take your questions and comments in our Overtime segment (56:10) - enjoy! Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more! Go to TempoMeals.com/WINGEDWHEEL  for 60% off your first box! #ad Go to KoffeeKult.com and use code WWP for 15% off your order! #ad Support the Jamie Daniels Foundation through Wings Money on the Board: https://www.wingedwheelpodcast.com/wingsmotb Best Contracts Article: https://www.nytimes.com/athletic/6513956/2025/07/29/nhl-best-contracts-2025-jack-hughes-brandon-hagel/

Howie and Harlan are joined by public health communicator Katelyn Jetelina for updates on COVID-19 and other issues, and to discuss how her emails to students and colleagues in the early days of the pandemic turned into a platform with global reach. Harlan looks at how AI is being used on both sides of the battle between providers and insurers over claims; Howie reports on a setback with a promising gene therapy for Duchenne muscular dystrophy. Links: Insurance Claims, AI, and Wearables “Elevance Health Reports Second Quarter 2025 Results” “Elevance lowers profit outlook, warns things will get worse for health insurers ““Blue KC wrongfully denied medical diagnoses, hospital alleges in AI-driven claims lawsuit” “Oscar Health cuts full-year guidance, estimates 2025 loss as ACA marketplace stumbles” Whoop “WHOOP Delivers Innovative Blood Pressure Insights for a Deeper Look at Your Well-Being” “Introducing Heart Screener: A smarter way to stay connected to your heart health” “Whoop says FDA is ‘overstepping its authority' with warning about blood pressure feature” FDA: WARNING LETTER, WHOOP, Inc. “RFK Jr. wants everyone to use wearables. What are the benefits, risks?” “Apple to Sell Watches With Blood-Oxygen Feature Disabled After Legal Setback” Your Local Epidemiologist Your Local Epidemiologist “Poll: Trust in Public Health Agencies and Vaccines Falls Amid Republican Skepticism” “Popular epidemiologist lays out future path of public health communication” Yale School of Public Health: PopHIVE Katelyn Jetelina: “NIH: The quiet engine of science is being dismantled” Katelyn Jetelina: “Covid-19 in pockets, sugar cane isn't better, ticks march on, rescission cuts (vs. everything else), bright spots, and more” Mayo Clinic: Norovirus infection Katelyn Jetelina: “The show must go on...” Katelyn Jetelina: “Harassment against scientists is out of control” Katelyn Jetelina: “Medicaid cuts: The how and why” CDC: H5 Bird Flu: Current Situatio CDC: Current Epidemic Trends (Based on Rt) for States” CDC: Measles Cases and Outbreaks Treating Duchenne Muscular Dystrophy Cleveland Clinic: Duchenne Muscular Dystrophy (DMD) “FDA approves Sarepta's Duchenne gene therapy for nearly all patients” “AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial” “Patient dies in Sarepta gene therapy trial, adding to safety concerns” “FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths” “In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy” “Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

On this week's Inside Startup Investing, Dr. Nicole Paulk—founder & CEO of Siren Biotechnology—details her AAV gene-therapy “FedEx truck” that can deliver anti-tumor cytokines directly to brain cancers. Early animal data show 86 % complete responses; the FDA has signaled a fast-track path for Siren's first-in-human trial set for 2026. With analog comps like Keytruda earning $30 B a year, Siren's upside—and impact—could be enormous.Highlights include...Why viruses? AAV viruses don't cause disease in humans yet efficiently deliver genetic payloads; Siren re-engineers them to express anti-tumor cytokines.Twin “firsts.” Siren pursues the first AAV-based cancer therapy and the first single virus platform scalable to hundreds of indications.Animal data. >500 mouse models show 86 % complete responses; large-animal pig study indicates strong safety with real-world neurosurgical delivery.Clinical plan. Combined Phase 1/2 trial in adults with recurrent high-grade gliomas targeted for 2026 with potential for rare-disease (orphan) fast-track.Market context. Current SOC for brain tumors is largely ineffective; analogous immunotherapies like Keytruda generate ~$30 B annually.

Big Show + with GVP and Aazam Ali Nanji is on demand! In this hour, Zack Warden joins the show to discuss the importance of the trade deadline for the Toronto Blue Jays, thoughts on the series against the Yankees, and more.(27:24) GVP and Aazam discuss the Connor Zary contract situation with the team and player apart on AAV. Plus more on where he fits long-term with the Flames.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

Last week's public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene therapy Elevidys, a move the biotech has resisted. The deaths, and disputes between FDA and Sarepta, raise questions about the future of AAV gene therapies, as well as the future of FDA's platform technology designation. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the events surrounding Sarepta's gene therapies and discuss how FDA, industry and patient groups should come together to learn the lessons from the tragic, avoidable deaths.BioCentury's analysts also assess Monday's appointment of Stanford professor and biotech executive George Tidmarsh to lead FDA's Center for Drug Evaluation and Research, and check in on the latest trends in venture financings. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656537#biotech #biopharma #pharma #lifescience #GeneTherapy #AAVTherapy #Sarepta #Elevidys00:01 - Sponsor Message: IQVIA Biotech02:03 - Gene Therapy17:59 - Leading CDER27:00 - Venture ReportTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Chris Russell, with some insight from AMAC, analyzes whether AAV (average annual value), contract length, or guarantees are the main factors delaying Terry McLaurin's contract. They reference various events and audio clips from the negotiation process to support their conclusions

The second half of the season starts today for the Mariners as they take on the Astros for a 3-game series. In the past few years, the Mariners have not had success out the gate after the All-Star break. Bump & Curtis break down what the Mariners need to do to avoid a slow start to the second half. // Headline Rewrites: Nick Emmanwori and the Seahawks reached an agreement on a fully guaranteed rookie contract. Damian Lillard and the Trail Blazers are reuniting after two seasons spent apart in Milwaukee. TJ Watt and the Steelers agreed to a 3-year extension with an AAV of $41 million, making him the new highest paid defensive player. // With Nick Emmanwori and Elijah Arroyo finally signing their rookie contracts, what does this tell us about the Seahawks and how they are operating? The guys give us their takes on what this new style of wanting fully guaranteed money for rookie contracts means for this organization and the NFL. // During the All-Star break, Jerry Dipoto caught up some of the media to talk about the trade deadline. He feels like we have a fairly complete roster and would be looking for a move that would be meaningful. He is aware that there some rental players that would fit in this clubhouse but nothing is certain. How are we feeling about these statements? 

The Seattle Times’ Bob Condotta joins Bump & Curtis to give us a preview of this Seahawks team prior to the start of next week’s training camp. He also gives us his reaction to both Nick Emmanwori and Elijah Arroyo finally singing their rookie contracts. Could we see any contract extensions get done as we are less than a week away from training camp? // Headline Rewrites: Nick Emmanwori and the Seahawks reached an agreement on a fully guaranteed rookie contract. Damian Lillard and the Trail Blazers are reuniting after two seasons spent apart in Milwaukee. TJ Watt and the Steelers agreed to a 3-year extension with an AAV of $41 million, making him the new highest paid defensive player. // NFL Headlines: Lloyd Howell has resigned as NFLPA Executive Director after it was found out that he had a part-time role with a private equity firm that was approved to buy minority stakes in NFL Teams. He also expensed two strip club visits to the NFLPA expense card. Michah Parsons gave an update on his contract talks with the cowboys to the Undertaker. // In order for the Seahawks to be a playoff team this season, who needs to outperform expectations? Curtis thinks that if Cooper Kupp can exceed expectations it would help out Sam Darnold and allow this offense to be dominant. Bump says Kenneth Walker is the one player that needs to exceed expectations for this offense to find success. 

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Ralf Schmid, Ph.D., Associate Director of Preclinical Research at Novartis Biomedical Research, about the evolving use of large animal models in gene therapy development. Dr. Schmid discusses the current reliance on non-human primates (NHPs), their growing logistical and ethical challenges, and the emerging interest in alternatives like genetically engineered pigs and sheep. He outlines key considerations around safety, biodistribution, and immunogenicity that still necessitate large-animal testin —particularly for CNS-targeted AAV therapies — and emphasizes the need for thoughtful study design, responsible sourcing, and diversification in model systems. Dr. Schmid also previews his participation in the upcoming Next Generation Gene Therapy Vectors Summit and reflects on the future of preclinical safety testing in a landscape aiming to balance innovation, rigor, and compassion.Subscribe to the podcast!Apple | Spotify | YouTube

This episode is the third in a series hosted by Molecular Therapy Editor-in-Chief Joseph Glorioso, PhD, that will cover comprehensive reviews of critical developments in the field of gene and cell therapy over the past 25 years. In this episode, Dr. Glorioso will discuss the reviews, “Current trends in gene therapy to treat inherited disorders of the brain,” with author Beverly Davidson, PhD, The Children’s Hospital of Philadelphia, and “The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy,” with author Jeff Chamberlain, PhD, University of Washington School of Medicine. If you enjoy this deep dive into research that is critical to the field, check out two more ASGCT events happening this fall: Advancing Cell and Gene Therapies for Cancer and Breakthroughs in Targeted In Vivo Gene Editing. During these events – in October and November, respectively – you’ll be able to hear directly from researchers about their own work related to these topics, or you can submit your own abstract for possible presentation. We hope to see you there! Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.au Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Astellas is doubling down on gene therapy while others retreat. Richard Wilson, SVP at Astellas Gene Therapies, joins In Vivo to discuss why the company believes AAV technology will transform medicine despite current industry headwinds.

The Philadelphia Flyers were able to re-sign RFA Defenseman Cam York to a 5 year extension on Monday. The deal will have an AAV of 5.15 Million a year during that time. Also on tap for Tuesday the boys will be breaking down the offseason as a whole. They will review the Free Agents signed, trades made, picks from the draft and give their overall grades on the offseason. Be sure to drop your comments in the chat and be a part of the show! Make sure you hit that like and subscribe wherever you watch or listen to Flyers Talk A2D!Like, Comment, and Subscribe for more!/ a2dradio  Facebook:   / a2dradio  Instagram:   / a2dradio  X:   / a2dradio  Website: http://a2dradio.com/_______________We thank you for your support!Specialized Physical Therapy:https://specializedphysicaltherapy.com/Boaggiosbread: https://boaggiosbread.com/Alan Foy:https://www.exprealty.com/

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness. Built on the foundational science of Dr. Jean Bennett and leveraging the legacy of Luxturna, Magrath shares how Opus is developing subretinal AAV-based therapies targeting seven distinct mutations. He also explains why gene therapy is particularly well-suited to IRDs, shares compelling early clinical data, and discusses the promise of early intervention in preserving vision and enabling proper neural development. Subscribe to the podcast!Apple | Spotify | YouTube

(00:00) Joe Murray and Matt McCarthy filling in for Toucher and Hardy today. Started off the day very strong talking about catholic school, the movie Departed and Marky Mark and the Funky Bunch. (22:09) WHAT HAPPENED LAST NIGHT: Bruins signed Tanner Jeannot for five years for 3.4 million AAV. Joe and Matt aren’t too thrilled about the signing to say the least. The Red Sox were winning 2-1 at the top of the 4th against the Reds last night until it got suspended due to the lightning storm. How delusional is the Red Sox Management? CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardy For the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston’s home for sports!

Free agency is in full swing, and we're back with another offseason edition of Oilersnation Everyday to break down all the action from Day 1 and beyond.The Edmonton Oilers made a notable addition on July 1st, signing Andrew Mangiapane to a 2-year deal worth $3.6 million AAV, adding another versatile piece to their top nine. While the Oilers lost Connor Brown and Corey Perry to the open market, they also added Matt Tomkins and Riley Stillman on two-way contracts to strengthen their depth chart.We'll recap everything the Oilers did on Day 1, explore what their next moves might be, and evaluate how their offseason is shaping up so far. Could they still target a bargain-bin forward or veteran defenseman? Is a trade still on the table?We'll also go around the league to talk about the biggest signings from Day 1 of free agency, deliver our One Big Take, ask The Giant Question, and close out the show with some picks from Bet365.Website: https://oilersnation.com/ https://twitter.com/OilersNation/ https://www.youtube.com/@Oilersnationdotcom/ https://www.facebook.com/OilersNation/https://www.instagram.com/oilersnationdotcomhttps://www.tiktok.com/@oilersnation SHOUTOUT TO OUR SPONSORS!!

Free agency day means a fresh episode of Oilersnation Radio is ready to massage your earholes and bring you up to date on everything going on with the Edmonton Oilers. On today's podcast, the fellas discussed the Evan Bouchard extension, the NHL Draft, Kasperi Kapanen, and much more.We kicked off the Monday episode of ONR with a delicious debate about where everyone is at with Evan Bouchard's four-year, $10.5m AAV contract, and whether it's not more of a problem that Bowman wasn't able to lock in the max term. We also discussed the Oilers re-signing both Kasperi Kapanen and Noah Philp before they were able to reach free agency, likely with the plan of having both of these players start on the opening day roster. Chances are, the Oilers are going to be tight for cap space when October rolls around, and they'll need cheaper deals on the books to fill holes in the roster.With plenty of time left to go until the deals slow down, the boys walked through some of our former friends who signed elsewhere on Tuesday, including Corey Perry's new deal in Los Angeles and Connor Brown's contract in New Jersey. While we all expected a quieter day in Edmonton given the team's lack of cap space, that doesn't make it any easier to see contributing roster players sign for big smoke in other markets. Regardless, the deals signed in the early hours on July 1st don't mean the Oilers are anywhere close to done, but that didn't stop many Oilers fans from being disappointed anyway.Regardless of what the Oilers have done or haven't done yet, there's little doubt that teams are spending big money on free agents with the salary cap expected to fly up over the next handful of years. In fact, one could make the argument that the Oilers could be better off avoiding some of these overpriced free agents, especially with the dollars that some mid-tier UFAs are signing on extended deals. Is that coping? Potentially yes. Hosted on Acast. See acast.com/privacy for more information.

The Mitch Marner saga has come to an end. The Golden Knights hand Toronto Maple Leafs have worked out a sign and trade to send Marner to Vegas on a brand new 8 year, $12m AAV contract, with Nic Roy going back the other way to Toronto. Subscribe to The Jesse Blake Sports Report YouTube Channel: https://www.youtube.com/@JesseBlakeTV?sub_confirmation=1Follow Jesse on Twitter at @JesseBlakeFollow Jesse on Instagram @Jesse.BlakeVisit https://sdpn.ca for more.Join us on Discord: https://discord.com/invite/MtTmw9rrz7For general inquiries email: info@sdpn.caReach out to https://www.sdpn.ca/sales to connect with our sales team and discuss the opportunity to integrate your brand within our content!Join SDP VIP:YouTube: https://www.youtube.com/channel/UC0a0z05HiddEn7k6OGnDprg/joinApple Podcasts: https://apple.co/thestevedanglepodcastAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Friday afternoon means a fresh episode of Oilersnation Radio is ready to be enjoyed. On today's podcast, the fellas discussed what's to come for the Oilers, Trent Frederic's new contract, the NHL Draft, free agency, and much more.We kicked off the Friday episode of Oilersnation Radio with a delicious debate about the Trent Frederic contract extension and what everyone's first thoughts are on the deal. From the max-term contract to the $3.85m AAV to the no-trade protection of various types throughout the life of the contract, the boys had plenty to say about our newest long-term friend.Changing gears, we explored some of the latest news and rumours surrounding the Oilers as they head into the offseason, and assessed the realism of these ideas given the team's limited cap space. Naturally, we all have high hopes that Stan Bowman will be able to make some magic happen, but we all know that many of the hopes and dreams we all have for the franchise. Finally, we wrapped up the Friday episode of ONR with another round of Ask the Idiots, betting talk for our friends at bet365, and Hot and Cold Performers to look back on the week. With the NHL Draft and free agency on deck, the guys spent the bulk of the Friday episode talking about what to expect over the next week, and how the Oilers could look like a much different hockey team by this time next week. Hosted on Acast. See acast.com/privacy for more information.

John Tavares is sticking around! He and the Toronto Maple Leafs have reached a 4 year contractr extension worth $4.38m AAV.Subscribe to The Jesse Blake Sports Report YouTube Channel: https://www.youtube.com/@JesseBlakeTV?sub_confirmation=1Follow Jesse on Twitter at @JesseBlakeFollow Jesse on Instagram @Jesse.BlakeVisit https://sdpn.ca for more.Join us on Discord: https://discord.com/invite/MtTmw9rrz7For general inquiries email: info@sdpn.caReach out to https://www.sdpn.ca/sales to connect with our sales team and discuss the opportunity to integrate your brand within our content!Join SDP VIP:YouTube: https://www.youtube.com/channel/UC0a0z05HiddEn7k6OGnDprg/joinApple Podcasts: https://apple.co/thestevedanglepodcastAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

It's another offseason edition of Oilersnation Everyday and we've got breaking news to kick things off! This morning, the Edmonton Oilers officially signed Trent Frederic to an 8-year extension with an AAV of $3.85 million per season. We'll break down the contract details, discuss whether the term and value make sense for Edmonton's long-term plans, and look at what kind of role Frederic could play over the life of the deal.With the Oilers still tight to the cap, what comes next? Could Viktor Arvidsson be the next piece to move ahead of free agency to free up more space? We'll explore that possibility, and look at how the Oilers might be positioning themselves for further additions or extensions — especially with Evan Bouchard and Connor McDavid's situations looming large.We'll also be joined by former NHL defenseman Jason Demers, who will share his thoughts on the Frederic deal, Edmonton's cap strategy, and what else he thinks Ken Holland and the Oilers front office could be cooking up this summer.All that and more on today's show!Website: https://oilersnation.com/ https://twitter.com/OilersNation/ https://www.youtube.com/@Oilersnationdotcom/ https://www.facebook.com/OilersNation/https://www.instagram.com/oilersnationdotcomhttps://www.tiktok.com/@oilersnation SHOUTOUT TO OUR SPONSORS!!

In a truly stunning, out-of-left-field event, the Giants traded for slugger Rafael Devers. It really did come out of nowhere, but it's genesis was the discontent that was brewing in Boston after Devers was not being treated like a franchise player, being promised third base, only to have Alex Bregman usurp it. The Giants gave up relatively little as a price for securing Devers for the next 8 1/2 years. This was not a rental, and often 2 month rentals end up costing teams a LOT more than what the Giants gave up. All told, the Giants traded away Kyle Harrison, Jordan Hicks, and two prospects. Even the AAV for Devers is under what the market would bear now and certainly what it will bear in several years. Devers is in the prime of his career at age 28. Buster Posey made this happen, and he is the man right now. Eric, Willie, and Chad discuss this blockbuster and can't find a comp to it in recent Giants history. We are all excited, but if the Giants would just actually perform on the field. After briefly tying the Dodgers for first place in the NL West over the weekend, they have lost 4 in a row and 5 of 6 overall. Let's hope they snap out of it with the help of their new shiny star.@torturecastfacebook.com/torturecasttorturecast.com

One of the challenges of delivering gene therapies to the eye is that once a subretinal injection is made, the therapy's distribution is confined to the margins of the pocket of fluid that is created, known as a bleb. Atsena, which is developing gene therapies for X-linked retinoschisis and Leber congenital amaurosis 1, uses its AAV.SPR technology that allows the gene therapy to spread laterally after injection. We spoke to Patrick Ritschel, CEO of Atsena Therapeutics, about the challenges of gene therapies for inherited retinal diseases, how the company's unique vector technology addresses this, and how it allows for safer and more effective delivery of gene therapies to the retina.

The Stanley Cup Final loss still stings, but the focus has now fully shifted to the future. On today's edition of Oilersnation Everyday, Tyler, Liam, and Producer Bordzy dissect what's shaping up to be a pivotal offseason for the Edmonton Oilers.Will Connor McDavid commit long-term and sign an extension this summer? Could the team explore moving on from Darnell Nurse and his hefty cap hit after another frustrating playoff run? These are just a few of the major questions we'll try to answer on the show.We'll also project what next season's lineup could look like and explore some possible offseason moves — especially in net. Is Stuart Skinner still the guy? And if so, who could the Oilers bring in to form a more reliable tandem?Plus, we'll break down the news of the weel: Will Trent Frederic stay in Edmonton? The Oilers and Frederic have been linked to an 8-year extension with an AAV of $4 million per season. We'll give our thoughts on the potential deal, what it could mean for the team's cap structure moving forward, and why management feels Frederic was a long-term fit for this core.We're also joined by What Chaos! host DJ Bean to get his perspective on the Oilers' playoff run, the sting of back-to-back Stanley Cup Final losses, and what Edmonton needs to prioritize if they want to finally get over the hump next season.It's a loaded offseason edition of the show — let's get into it.Website: https://oilersnation.com/ https://twitter.com/OilersNation/ https://www.youtube.com/@Oilersnationdotcom/ https://www.facebook.com/OilersNation/https://www.instagram.com/oilersnationdotcomhttps://www.tiktok.com/@oilersnation SHOUTOUT TO OUR SPONSORS!!

Ben and Brent continue the hockey talk into the final hour on Monday. The hosts welcome on Daily Faceoff insider, Frank Seravalli, to break down the Stanley Cup Final. He debates if Edmonton's goaltending situation is one of the main reasons they're a game away from losing the championship in consecutive years. They then look ahead to the upcoming free agent market and parse through some of the top names set to hit the market. They discuss if Brad Marchand could get a higher AAV than Sam Bennett and what Mitch Marner will be seeking. The morning duo then check in with Blue Jays Central analyst, Madison Shipman (28:55), to talk about Toronto's MLB team and how they can reset returning to Rogers Centre this week after getting swept to close out their road trip. The trio discuss Vladimir Guerrero Jr.'s tendency to walk over hitting for power, as well as what has made Alejandro Kirk so consistent and productive this season.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

In honor of Molecular Therapy’s 25th anniversary, this episode is the second in a series hosted by Dr. Joseph Glorioso, Editor-in-Chief of Molecular Therapy, that will cover comprehensive reviews of critical developments in the field of gene and cell therapy over the past 25 years. In this episode, Dr. Glorioso will discuss the reviews, AAV vector development, back to the future, with author Sheila Mikhail; M34, Inc.; and The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy; with author Dr. Mark Kay, Stanford University. If you enjoy this deep dive into research that is critical to the field, check out two more ASGCT events happening this fall: Advancing Cell and Gene Therapies for Cancer and Breakthroughs in Targeted In Vivo Gene Editing. During these events – in October and November, respectively – you’ll be able to hear directly from researchers about their own work related to these topics, or you can submit your own abstract for possible presentation. We hope to see you there! Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

The Colorado Avalanche have locked in their 2C with Brock Nelson signing a three year $7.5 million AAV contract with the team. The First piece to the Avs postseason puzzle is set, what does mean for the Avs and what comes next? Intro - 0:00First reactions - 1:00Skating Data - 6:25High danger scoring - 20:35A bit much? - 31:30Still some work to be done, but..- 38:00Where's the snarl? - 58:15Wrapping up - 1:02:00 An ALLCITY Network Production PARTY WITH US: https://thednvr.com/events ALL THINGS DNVR: https://linktr.ee/dnvrsports MERCH: https://store.allcitynetwork.com/collections/dnvr-locker SUBSCRIBE: https://www.youtube.com/c/DNVR_Sports Toyota: Visit Your Front Range Toyota Stores at a location near you - Toyota is the official vehicle of DNVR. Toyota - Let's Go Places! First Bank: So, if you're ready for better banking and the chance to earn a little extra, head to efirstbank.com/bonus. Certain restrictions and requirements apply. Member FDIC. Hall of Fame App: Get a 7-Day Free Trial + 50% Off your first month with code DNVR. Just download the HOF app on iOS and Android or visit www.hofbets.com, enter code DNVR, and you're all set. #ad Monarch Money: Use Monarch Money to get control of your overall finances with 50% off your first year at https://www.monarchmoney.com/dnvr bet365: Go to https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLERUCHealth: Learn more about Living Like There's A Tomorrow at https://www.uchealth.org/tomorrow/?utm_source=DNVR&utm_medium=Audio&utm_campaign=Brand_LLTIAT_Null_JFMFY25_AW_Null Coors Light:  Delivery on Instacart at https://coorslight.com/DNVR. Celebrate Responsibly. Coors Brewing Company, Golden, Colorado. Gametime: Download the app, create an account, and use code DNVR for $20 off your first purchase. Terms apply. Shady Rays: Head to https://shadyrays.com and use code: DNVR for 35% off polarized sunglasses. Try for yourself the shades rated 5 stars by over 300,000 people. Get 10 FREE meals at https://hellofresh.com/freeavalanche. Applied across 7 boxes, new subscribers only, varies by plan. https://www.bet365.com/hub/en-us/app-hero-banner-1?utm_source=affiliate&utm_campaign=usapp&utm_medium=affiliate&affiliate=365_03485318 or use code DNVR365 when you sign up. Must be 21+ and physically located in CO.  Please gamble responsibly. If you or someone you know has a gambling problem and wants help call or TEXT 1-800-GAMBLER When you shop through links in the description, we may earn affiliate commissions. Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing.#coloradoavalanche #hockey #hockeypodcast

We have another busy day to get through all the Philadelphia Flyers news and rumors floating around.First, Noah Cates is Danny Briere's most recent piece of business, signing an extension today for 4 years with a $4 million AAV.Also, Roger McQueen has said he's 10/10 healthy following a misdiagnosis of his back injury. If the 6-5 center prospect is truly 100%, can the Flyers afford to pass on him if available at #6?There's also Charlie's first Mock Draft, a Brent Flahr Q&A in the Inquirer, and more!

Sunday May 18, 2025. Week 21   Show notes on the site: https://curesyngap1.org/podcasts/syngap10/    CAMP4 Press Release https://investors.camp4tx.com/news-releases/news-release-details/camp4-presents-translational-data-syngap1-related-disorders Dr. Yuri at WODC: https://www.youtube.com/watch?v=oNwgo7TmrVo Presentation at ASGCT: https://investors.camp4tx.com/news-events/presentations GETA Talk: https://www.facebook.com/Syngapresearch/posts/pfbid08Aztex32vdwNZduVkPQeG353W49Dhq8iKJeZEkajKUmkeUiDdCwzyqa9ndEVpdCUl    To get these Therapies to kids the NHS data is key, ProMMis CHOP - Email them ENDD@chop.edu Stanford (Singed!) - https://curesyngap1.org/blog/srf-announces-stanford-launches-california-synaptopathy-clinic/ CHCO - https://curesyngap1.org/blog/visiting-syngap1-natural-history-study-childrens-hospital-colorado-chco/ Citizen Health https://cureSYNGAP1.org/Citizen is at 267, why not 300?   Hopkins article featuring SRF - Competition is good for the patient FB https://www.facebook.com/cureSYNGAP1/posts/pfbid07MP7St3zdxLKYXTJULKa5S35YvgL6AJndenHicedxU3rtQF6iY1wwwNUoDuUD9cpl LI https://www.linkedin.com/posts/curesyngap1_nih-cuts-stalling-progress-on-rare-genetic-activity-7328449817074946048-AAsB   ASGCT Mouse poster for Q504X from the JAX, Dr. Matt Simon Conf Video https://www.youtube.com/watch?v=loYXkkTSUIY  Presentation on AAV for SYNGAP1 at Allen by Dr. Megan Quinlan   What about this guy? Gift link: https://www.nytimes.com/2025/05/15/health/gene-editing-personalized-rare-disorders.html?unlocked_article_code=1.H08.E-oX.t5bo6kxJGUOU&smid=url-share  PBS: https://www.youtube.com/watch?v=dOeiPoa3gvM Eric Topol: https://erictopol.substack.com/p/the-first-human-to-undergo-in-vivo   More incredible news https://news.unl.edu/article/husker-team-wins-second-round-prize-in-nih-gene-editing-challenge   REPURPOSING Mike's post in private SRF Group: https://www.facebook.com/groups/syngap #Amlexanox with Fortuity Pharma. https://fortuitypharma.com/    Butyrate Update https://aesnet.org/abstractslisting/phenylbutyrate-for-syngap1-related-developmental-and-epileptic-encephalopathy Trial ending at year end, working with SLC6A1 and Rachel Heilmann to continue coverage, then we can scale, once we have a paper. SunButyrate https://a.co/d/7kiHXS8    PUBMED  328 total with 20 YTD https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&sort=date&sort_order=asc&timeline=expanded Sleep https://www.sciencedirect.com/science/article/abs/pii/S1389945724005793?via%3Dihub   SRF Fundraisers MDBR with AJH and HM https://curesyngap1.org/calendar/million-dollar-bike-ride-2025/   Well done to Tavilla and Jones!  We are over $221k Tavilla clears $160k for Sprint. https://donate.curesyngap1.org/campaign/sprint4syngap2025/c660255   Porter Jones and his friends William, Patrick, and Judson raised over $10k in doughnuts, this netted over $8k because people donated.  Amazing and thank you to Krispy Kreme.  https://donate.curesyngap1.org/event/sweets-for-syngap1/e678677   SRF PROFILES Vicky post in Mexico https://www.linkedin.com/posts/victoria-arteaga-26913433_diagnostico-epilepsia-syngap1-activity-7329725268003069953-R41P Vicky's Siblings Violeta and Lourdes, sisters to Amelia https://curesyngap1.org/syngap-siblings/ Harper Albrecht Wednesday Warrior #215 parents Ashley and Justin https://cureSYNGAP1.org/Warrior   PREREGISTER FOR THE CURE SYNGAP1 CONFERENCE https://curesyngap1.org/calendar/cure-syngap1-conference-2025-hosted-by-srf/